Virology News
207.7K views | +1 today
Virology News
Topical news snippets about viruses that affect people.  And other things. Like Led Zeppelin. And zombies B-)
Curated by Ed Rybicki
Your new post is loading...
Your new post is loading...
Scooped by Ed Rybicki
February 26, 2016 7:23 AM
Scoop.it!

Specific IgG Subclasses Induced in Late Boost Vaccination of RV144 Subjects

Specific IgG Subclasses Induced in Late Boost Vaccination of RV144 Subjects | Virology News | Scoop.it

While RV144 vaccine-induced IgG3 to HIV-1 Env variable loops 1 and 2 (V1V2) correlated with decreased risk of HIV-1 acquisition, the responses were not durable. We studied IgG subclasses (IgG1-IgG4) in HIV-uninfected RV144 volunteers who completed their primary vaccination series 6-8 years earlier and were randomized to receive booster vaccinations with either ALVAC-HIV/AIDSVAX B/E (Gr1), AIDSVAX B/E (Gr2) or ALVAC-HIV (Gr3) at 0 and 6 months (RV305).

ELISA IgG1-IgG4 to HIV gp120 A244gD, and gp70V1V2 scaffold proteins 92TH023 (subtype AE) and CaseA2 (subtype B) were assessed in plasma and cervico-vaginal mucus (CVM) at study entry, 2 weeks post 1st and 2nd boosts, and 6 and 12 months post 2nd boost.

At study entry, geometric mean titers (GMT) of IgG to gp120 A244gD in plasma ranged from 50-67 in all groups. We did not detect a boosting effect of any IgG subclasses in plasma and CVM in Gr3. IgG1 GMT increased 2 weeks post 1st boost in Gr1 and Gr2, but significantly declined (p<0.01) 6 months post 2nd boost (Gr1=4850 and 255; Gr2=5279 and 252, respectively). They were significantly higher than those in RV144 at peak immunogenicity and 6 months post last injection (492 and 88, p<0.01). IgG3 GMT increased 2 weeks post 1st boost (Gr1=168, Gr2=159), but not after the 2nd boost, and were significantly lower than RV144 at peak immunogenicity  (532, p<0.01). While IgG4 was undetected in RV144, it increased to 951 and 611 and to 800 and 588 2 weeks post 1st and 2nd boosts in Gr1 and Gr2, respectively. IgG1-IgG4 to gp70V1V2 scaffolds was not detected at study entry. IgG1 GMT to AE and B V1V2 were similar in Gr1 and Gr2 after the 1st boost (Gr1-Gr2/AE=528-524 and Gr1-Gr2/B=50-43) but lower after the 2nd boost (Gr1-Gr2/AE=146-147 and Gr1-Gr2/B=28-24). IgG4 to AE and B V1V2 were detected in Gr1 and Gr2 but not detected in RV144. RV144 IgG3 to V1V2 scaffolds were not boosted in Gr1 and Gr2, and IgG2 remained weak for all antigens tested. In CVM, most responses to gp120 A244gD were IgG1 and IgG4, while to scaffolds were mostly IgG1.

Late boosts with AIDSVAX B/E, with or without ALVAC-HIV, induced plasma HIV-specific IgG responses that were predominantly IgG1 and IgG4, were significantly higher than RV144 responses, but did not improve magnitude nor durability of IgG3, and were similar to subtypes in CVM. These studies highlight the need for new strategies to durably boost HIV-specific, protective antibody responses observed in RV144.

No comment yet.
Scooped by Ed Rybicki
February 26, 2016 7:17 AM
Scoop.it!

Immunogenicity and Efficacy of ALVAC-HIV/gp120-Clade C in Alum Regimen in Macaques

Immunogenicity and Efficacy of ALVAC-HIV/gp120-Clade C in Alum Regimen in Macaques | Virology News | Scoop.it
Abstract Body: 

The RV144, a phase 3 trial held in Thailand, reduced the risk of HIV infection by 31.2%. In our lab we replicated the results of this study in a SIVmac251 models using an ALVAC/SIV-gp120/Alum Alhydrogel vaccine (44% vaccine efficacy). A trial has begun in South Africa (SA) to test a similar vaccine using clade C immunogens. We design a study in which we tested the ALVAC HIV/gp120 Clade C Alum in macaques model

27 all-female Indian rhesus macaques received at weeks (wk) 0, 4, 12 and 24 intramuscularly 10^8 PFU of both ALVAC vCP172 expressing SIV gag-pol and another and ALVAC vCP1521 expressing ZM96 Clade C HIV gp120 env trans-membrane anchor and the Clade B gag, pro. 200μg of each gp120 (TV1 and 1086) in alum hydroxide (proprietary formulation) were given at weeks 12 and 24. 20 controls received only Alum. 4 wk after last immunization, all the animals were challenged with repeated low doses SHIV1157ipd3N4 via vaginal route 17 times

Plasmablasts (PBs) frequency increased 1 wk after the last vaccination (p=0.0005) while the α4β7 subset decreased (p=0.0010) and the CXCR3+ did not changed. Serum antibodies titer to 1086 peaked at week 26 (>10^6) in vaccinated animals that did not became infected and maintained a title > then 10^4 up to 48 wks. Plasma Abs elicited were able to neutralize only tier 1 Clade C viruses. Mucosal antibodies to V2 were higher in the vaginal mucosa then in the rectal. PBs CXCR3+ correlated with antibodies to V1/V2 antigens. Surprisingly we observed no reduction in the risk of SHIV acquisition in the vaccinated animals, nor protection from high viral load, nor CD4 loss. However animals that were infected later had higher titer of Ab titer in plasma at wk 28 to 1086

The lack of vaccine effect was surprising given the efficacy observed in a similar vaccine tested in the SIVmac251 model. However the α4β7 plasmablasts frequency differed in the two vaccine regimens. This difference might be due to differences in the adjuvants used in the two vaccine regimes that might also influenced differences in vaccine efficacy.

 
 
No comment yet.
Scooped by Ed Rybicki
February 26, 2016 7:11 AM
Scoop.it!

Conserved Element DNA Vaccine based on HIV-1 or SIV sequences Increases T-cell Breadth

Conserved Element DNA Vaccine based on HIV-1 or SIV sequences Increases T-cell Breadth | Virology News | Scoop.it

Background: HIV sequence diversity and potential “decoy” epitopes are hurdles in the development of an effective AIDS vaccine. We tested the hypothesis that a vaccine candidate composed of highly Conserved Elements (CE) of the HIV proteome excluding the variable regions would help overcome these problems. CE were selected based on both stringent conservation and association of specific elements with immune control. A prototype HIV DNA vaccine, expressing 7 CE identified in p24gag as a single protein, was able to induce robust cross-clade specific immune responses in mice. Methodology: Macaques were immunized by IM injection followed by electroporation with two DNA plasmids providing potential epitopes found in >99% of all HIV-1 M group sequences. Cellular immune responses were compared to those obtained upon vaccination with gag DNA only. As a second test of this concept, we also developed SIVp27gag CE vaccine and tested immunogenicity in DNA vaccinated macaques. Results: HIV CEgag DNA vaccination induced robust immunity in all 10 vaccinated macaques, whereas full-length gag DNA vaccination elicited CE responses in only 5 of 11 animals targeting fewer CE per animal. CE DNA vaccination elicited highly cytotoxic T cells against CE, capable of Granzyme B production and degranulation, desired features for an effective vaccine. Importantly, boosting CE-primed macaques with DNA expressing full-length p55gag increased both magnitude of CE responses and breadth of Gag immunity, demonstrating altered immunodominance hierarchy in the presence of pre-existing CE-specific responses. Similarly, we found the vaccination with SIV p27gag CE induced antigen-specific responses. In contrast, vaccination with SIV p57gag induced poor CE-specific responses found only in 50% of the vaccinees. As for HIV CE, the SIV CE-specific responses were boosted by vaccination with DNA expressing complete Gag. Conclusions: Combination of conserved elements and full-length immunogen provides a novel strategy to increase the magnitude and breadth of immune responses to Gag, and allows for the development and expansion of subdominant responses. This vaccine allows the immune system to target the ‘Achilles heel’ of the virus, for which few escape pathways exist. Inclusion of a conserved element immunogen provides an effective strategy to broaden responses against any highly diverse pathogen by avoiding decoy epitopes, while focusing responses to critical and invariable viral elements.

 
 
No comment yet.
Scooped by Ed Rybicki
February 26, 2016 7:06 AM
Scoop.it!

HIV-1 Infection During Recombination Procedures With Defective Constructs

HIV-1 Infection During Recombination Procedures With Defective Constructs | Virology News | Scoop.it

An accidental contagion during the production of theoretically non-infectious HIV-1 laboratory-recombinant viruses, used only for research purpose, is here described.

HIV-1 infection was diagnosed by ELISA assay, confirmed by Western Blot, and HIV-RNA/DNA test. Baseline plasma samples were used for routine pol and V3 sequences, PBMC for the whole HIV-1 genome sequencing and for in-vitro isolation. Phylogenetic analyses using Neighbor Joining (NJ) and Maximum Likelihood (ML) methods revealed the source of infection. Ethics committee approval and signed informed consent were obtained.

A lab worker resulted HIV-1 positive during a routine screening HIV test. In the 6 months preceding HIV diagnosis, he/she exclusively worked on the production of a recombinant nef-defective HIV, starting from a nef/env-defective NL4.3 vector and JRFL env-encoding plasmid. In the same laboratory other HIV-1 constructs were handled by other researchers at the same time. A thorough investigation did not evidence any laboratory accident during the whole period. At diagnosis, CD4 were 392 cells/μL, HIV-RNA 3.30 log cps/mL, and HIV-DNA 157 cps/106 PBMC. Virus was R5-tropic. After 25 months of stable HIV-1 RNA and CD4-cells, a sudden 1-log HIV-RNA increase occurred; TDF/FTC/RPV cART was started, with full viremia control.

NJ trees revealed a B-subtype virus, totally unrelated with other 629 HIV-1 clinical strains collected at the same hospital, but clustering exclusively with NL4.3 for pol sequence, and with JRFL for V3 (bootstrap: 96% and 100%, respectively). Genetic distance confirmed the homology of pol and V3 with NL4.3 and JRFL, respectively (0.002±0.002 and 0.000±0.000). Full-length viral sequence, performed in a different laboratory, confirmed the results and revealed a NL4.3/JRFL recombinant strain surprisingly expressing nef. A primary isolate obtained from his/her PBMC culture confirmed the nef-expressing NL4.3/JRFL recombinant strain. By inferring ML trees, the entire HIV-1 genome clustered again with NL4.3 (bootstrap>99%), with the exception of env (strongly linked with JRFL, bootstrap=99.7%). To date, how nef gene (absent in both vectors) entered into the recombinant virus, and mode of contagion, remain both unclear.

This clinical case highlights that in-vitro recombination procedures with per se non-infectious vectors, in a laboratory handling multiple HIV constructs, may still represent a risk of HIV contagion notwithstanding increasing biosafety efforts.


 
Ed Rybicki's insight:

Frightening.  SERIOUSLY frightening - and may lead to a rethink of what biosafety level "non-infectious" HIV constructs require!!

No comment yet.
Scooped by Ed Rybicki
February 25, 2016 3:57 AM
Scoop.it!

Here's Why It's a Very Bad Idea to Wipe Mosquitoes Off the Face of the Earth

For humans, it's likely the most lethal animal in the world, spreading malaria, Zika, dengue, and other fatal diseases, but killing off all the world's species of mosquitoes would likely have far reaching consequences.
No comment yet.
Scooped by Ed Rybicki
February 23, 2016 5:41 AM
Scoop.it!

"Zika is Possibly the Scariest Virus Since HIV!" Oh, please!

"Zika is Possibly the Scariest Virus Since HIV!" Oh, please! | Virology News | Scoop.it

Normally, we ignore or downplay infectious disease scares. As is the case with so many other scares, the eventual outcome rarely resembles the scare, let alone being worthy of the media hysteria surrounding it.

Even though it is invoked every year at the start of the flu season, we have not had anything close to the 1918-19 flu pandemic. In 2014, Ebola did some awful damage in isolated regions of Africa but did not engulf the world. As scary as it seemed a few years ago, anthrax barely moved the needle in the U.S.

Ed Rybicki's insight:

And that is the most hysterical title I have seen on anything about Zika except maybe the conspiracy theory posts.  Otherwise, reasonalby sensible message!

No comment yet.
Scooped by Ed Rybicki
February 23, 2016 5:27 AM
Scoop.it!

Ronnie Wood's wife leaves Brazil over Zika virus fears

Ronnie Wood's wife leaves Brazil over Zika virus fears | Virology News | Scoop.it
Rolling Stones guitarist Ronnie Wood says his pregnant wife has left Brazil to avoid exposure to the Zika virus.
Ed Rybicki's insight:

Had to get rock 'n roll in there somehow!

No comment yet.
Scooped by Ed Rybicki
February 23, 2016 4:11 AM
Scoop.it!

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial

Vaginal Ring Provides Partial Protection from HIV in Large Multinational Trial | Virology News | Scoop.it

NIH-Funded Study Finds Protective Effect Strongest in Women over Age 25

 
Woman holding the dapivirine vaginal ring tested in the NIH-funded ASPIRE study.
Credit: International Partnership for Microbicides

A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found. The ring reduced the risk of HIV infection by 27 percent in the study population overall and by 61 percent among women ages 25 years and older, who used the ring most consistently.

These results were announced today at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston and simultaneously published online in the New England Journal of Medicine.
Ed Rybicki's insight:

A great study, with significant South African and UCT contributions.

No comment yet.
Scooped by Ed Rybicki
February 22, 2016 9:43 AM
Scoop.it!

Antibody Alternatives: building reagents

Antibody Alternatives: building reagents | Virology News | Scoop.it
Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.
No comment yet.
Scooped by Ed Rybicki
February 22, 2016 8:06 AM
Scoop.it!

Vaccine Has Sharply Reduced HPV in Teenage Girls, Study Says

Vaccine Has Sharply Reduced HPV in Teenage Girls, Study Says | Virology News | Scoop.it
A vaccine for human papillomavirus, which causes cervical cancer, has reduced its prevalence in teenage girls by almost two-thirds, the study said.
No comment yet.
Scooped by Ed Rybicki
February 22, 2016 6:00 AM
Scoop.it!

Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection

Increased risk of hepatic complications in kidney transplantation with chronic virus hepatitis infection | Virology News | Scoop.it
Data regarding the risk of various liver diseases among different hepatitis viruses in kidney transplantation have not yet been identified.We selected individuals with kidney transplantation (ICD-9-CM V420 or 996.81) from 2000–2009 from the catastrophic illness registry of National Health Insurance Research Database (NHIRD)as the study cohort.
No comment yet.
Scooped by Ed Rybicki
February 22, 2016 5:56 AM
Scoop.it!

Big boost in detecting Zika virus in Kenya

Big boost in detecting Zika virus in Kenya | Virology News | Scoop.it
Kenya's capacity to detect the dreaded Zika virus has received a big boost as jitters over the diseases spreads across the globe.
No comment yet.
Scooped by Ed Rybicki
February 22, 2016 5:55 AM
Scoop.it!

Scotland’s rabbit population ‘decimated’ by virulent virus

Scotland’s rabbit population ‘decimated’ by virulent virus | Virology News | Scoop.it
Rabbits are being wiped out across the UK by a deadly new strain of a virus which could be as fatal for wildlife as myxomatosis, experts have warned.
No comment yet.
Scooped by Ed Rybicki
February 26, 2016 7:20 AM
Scoop.it!

DNA and Protein Co-immunization Improves the Magnitude and Longevity of Humoral Immune Responses

DNA and Protein Co-immunization Improves the Magnitude and Longevity of Humoral Immune Responses | Virology News | Scoop.it

Background: Understanding the quality of immune responses induced by different vaccine regimens is essential for improving the prospects of AIDS vaccines. Methodology: To identify optimal regimens, we compared vaccination protocols that used DNA, protein, or a combination of DNA and protein using a classical prime/boost strategy or delivered in a co-immunization regimen combining the two vaccine components. Magnitude, breadth, longevity and mucosal dissemination of anti-Env humoral responses were monitored in vaccinated macaques. Rhesus macaques were vaccinated using electroporation with either DNA, DNA/protein co-immunization, or DNA prime followed by protein boost or by protein alone. As protein source, we used AT-2 inactivated SIV particles or HEK293 produced HIV or SIV Env. Humoral (including neutralizing, linear epitope and V1V2 antibodies) and cellular responses were followed over time. Some of the vaccinated macaques were challenged to determine immune correlates of protection. Results: Protein only vaccination induced robust humoral responses, which rapidly declined. In contrast, co-immunization with DNA (IM delivered by needle) and protein induced long-lasting responses. We expanded on these observations and implemented several vaccine improvements, i.e. better env DNA plasmids, inclusion of IL-12 DNA as adjuvant and improved in vivo DNA vaccine delivery by intramuscular injection followed by in vivo electroporation (IM/EP) and inclusion of protein as boost or co-immunization regimen. Although DNA only vaccination achieved strong humoral responses, protein boost after DNA vaccination greatly increased Ab levels. Importantly, a co-immunization strategy of DNA/protein injected in the same muscle the same time induced highest and broad humoral responses. Similar data were obtained using either purified Env proteins or inactivated viral particles. Inclusion of DNA in the vaccine promoted persistence of plasma antibody levels for greater than 2 years. SIV DNA/protein vaccination induced: higher SIV Env-specific IgG in saliva; more responders with higher SIV Env-specific IgG in rectal fluids; higher and longer-lasting plasma bAb and Nab to homologous and heterologous Env; and Ab to V1/V2. Systemic and mucosal vaccine-induced Ab responses against SIVsmE660 correlated with slower virus acquisition upon challenge. In addition, vaccinated macaques showed strong protection against chronic viremia compared to controls. Similar to SIV, HIV DNA/protein (purified Env) vaccination also induced higher Ab levels compared to DNA only, including significantly higher levels of V1/V2 Abs. Conclusions: DNA/protein co-delivery increases the magnitude and longevity of systemic and mucosal humoral immune responses in immunized rhesus macaques.

 
 
No comment yet.
Scooped by Ed Rybicki
February 26, 2016 7:14 AM
Scoop.it!

Immune Activation Impairs Yellow Fever Vaccine Efficacy in HIV-Infected Patients

Immune Activation Impairs Yellow Fever Vaccine Efficacy in HIV-Infected Patients | Virology News | Scoop.it

Conclusions: Treated HIV-infected individuals appear to have impaired and/or less durable neutralizing antibody responses to YFV than HIV-uninfected individuals, which were associated with lower CD4+/CD8+ ratio. These results suggest that a low CD4+/CD8+ ratio may be a better surrogate for functional immune defects than the CD4+ T cell count in treated HIV infection. Our findings are consistent with an emerging literature suggesting that CD4+/CD8+ ratio is a stronger correlate of chronic immune activation and predictor of mortality in this setting.

 
Ed Rybicki's insight:

Sinister....

No comment yet.
Scooped by Ed Rybicki
February 26, 2016 7:09 AM
Scoop.it!

Evaluation of HIV-1 Reservoir Characteristics in a Therapeutic Gag Vaccine Trial

Evaluation of HIV-1 Reservoir Characteristics in a Therapeutic Gag Vaccine Trial | Virology News | Scoop.it

Background: ACTG A5197 was a placebo-controlled trial of a therapeutic rAd5 HIV-1 gag vaccine in participants on suppressive antiretroviral therapy. The vaccine induced HIV-1 Gag-specific CD4+ interferon-γ-producing cells, which was correlated with lower viral rebound during an analytic treatment interruption (ATI). We investigated the effects of vaccination on HIV-1 reservoir characteristics prior to the ATI. Methodology: Participants received the vaccine/placebo at study weeks 0, 4, and 26 prior to a 16-week ATI at week 38. Cell-associated HIV-1 RNA and DNA (CA-RNA and CA-DNA) and HIV-1 residual viremia (RV) by a single-copy assay were quantified at weeks 0, 8, and 38. HIV-specific CD4+ and CD8+ activity were assessed by an intracellular cytokine staining assay. Results: At week 8, after two doses of the vaccine/placebo, modest differences between study arms were noted both in the levels of RV (vaccine [N=65] vs. placebo [N=30]: median 0.7 vs. 1.1 cp/mL, P=0.08) and proportions of individuals with detectable RV (37% vs. 57%, P=0.08). Participants in the vaccine arm with undetectable RV had a significantly higher frequency of both HIV-1 Gag-specific CD4+ interferon-γ-producing cells (undetectable [N=39] vs. detectable [N=24]: 277 vs. 161 cells/106 lymphocytes, P=0.03) and CD8+ interferon-γ-producing cells (undetectable [N=39] vs. detectable [N=24]: 1326 vs. 669 cells/106 lymphocytes, P=0.04). By week 38, however, no significant differences were observed in the numbers of Gagspecific CD4+ or CD8+ interferon-γ-producing cells between those with and without detectable RV in the vaccine arm. Therapeutic vaccination did not induce significant changes in CA-RNA or CA-DNA prior to ATI. At study entry, CA-RNA and CA-DNA levels were correlated with the numbers of HIV-specific CD4+ interferon-γ-producing cells (CA-RNA [N=93]: r = -0.23, P=0.03 and CA-DNA [N=93]: r = -0.28, P<0.01) and CA-RNA was associated with RV (r = 0.23, P=0.04, N=77). These associations weakened after vaccination and were not significant at weeks 8 and 38. Plasma HIV-1 RNA set point during the ATI was significantly associated with pre-ATI week 38 CA-RNA and CA-DNA (CA-RNA [N=90]: Spearman r = 0.51, P<0.01 and CA-DNA [N=93]: r = 0.47, P<0.01). Conclusions: Early in the vaccination course, higher frequencies of Gag-specific CD4+ and CD8+ cells were associated with lower levels of RV, but this effect waned over time. Higher pre-ATI CA-RNA and CA-DNA levels were associated with higher viral load set point during the ATI, but were not significantly altered by the therapeutic vaccine. In this study, therapeutic HIV vaccination induced HIV-specific T cells, but more potent immune responses may be needed to reduce the latent HIV-1 reservoir.

 
 
No comment yet.
Scooped by Ed Rybicki
February 25, 2016 6:07 AM
Scoop.it!

Ebola 'devastates long-term health' - BBC News

Ebola 'devastates long-term health' - BBC News | Virology News | Scoop.it
Most people who survive infection with Ebola will have long-term health problems, according to doctors.
No comment yet.
Scooped by Ed Rybicki
February 23, 2016 6:15 AM
Scoop.it!

Transient Bluetongue virus serotype 8 capsid protein expression in Nicotiana benthamiana

Transient Bluetongue virus serotype 8 capsid protein expression in Nicotiana benthamiana | Virology News | Scoop.it

Bluetongue virus (BTV) causes severe disease in domestic and wild ruminants, and has recently caused several outbreaks in Europe. Current vaccines include live-attenuated and inactivated viruses; while these are effective, there is risk of reversion to virulence by mutation or reassortment with wild type viruses. Subunit or virus-like particle (VLP) vaccines are safer options: VLP vaccines produced in insect cells by expression of the four BTV capsid proteins are protective against challenge; however, this is a costly production method. We investigated production of BTV VLPs in plants viaAgrobacterium-mediated transient expression, an inexpensive production system very well suited to developing country use. Leaves infiltrated with recombinant pEAQ-HTvectors separately encoding the four BTV-8 capsid proteins produced more proteins than recombinant pTRA vectors. Plant expression using the pEAQ-HT vector resulted in both BTV-8 core-like particles (CLPs) and VLPs; differentially controlling the concentration of infiltrated bacteria significantly influenced yield of the VLPs. In situ localisation of assembled particles was investigated by using transmission electron microscopy (TEM) and it was shown that a mixed population of core-like particles (CLPs, consisting of VP3 and VP7) and VLPs were present as paracrystalline arrays in the cytoplasm of plant cells co-expressing all four capsid proteins.

 
No comment yet.
Scooped by Ed Rybicki
February 23, 2016 5:32 AM
Scoop.it!

GM viruses could help prevent animal diseases jumping to humans

GM viruses could help prevent animal diseases jumping to humans | Virology News | Scoop.it
Vaccinating wildlife with genetically-modified viruses could one day help stop diseases like Ebola and MERS jumping from animals to humans, researchers say.
Ed Rybicki's insight:

In principle, a great idea - BUT, as was pointed out, using live viruses in an effectively uncontrolled manner COULD result in all sort of unforeseen outcomes.

Like making a killer virus that drastically reduces numbers of a given species, like myxomatosis and RHDV did to rabbits [OK, they were supposed to].

Like making a virus that spreads to NON-target animals, and does...what?  Start a zombie plague?  Mutate to virulence, and cause havoc?

The point is, WE DON'T KNOW what may happen - and in circumstances like that, it may be safer to leave well alone!

No comment yet.
Scooped by Ed Rybicki
February 23, 2016 5:26 AM
Scoop.it!

Gamma ray blasts to cut spread of Zika virus in Brazil

Gamma ray blasts to cut spread of Zika virus in Brazil | Virology News | Scoop.it
International Atomic Energy Agency sends irradiator to sterilise male mosquitoes, which will result in females laying infertile eggs
Ed Rybicki's insight:

Love that" gamma ray blasts" rather than just "irradiation" B-)

No comment yet.
Scooped by Ed Rybicki
February 23, 2016 3:39 AM
Scoop.it!

Evidence Mounts for Interbreeding Bonanza in Ancient Human Species

Evidence Mounts for Interbreeding Bonanza in Ancient Human Species | Virology News | Scoop.it
Nature tallies the trysts among Neanderthals, humans and other relatives
No comment yet.
Scooped by Ed Rybicki
February 22, 2016 9:08 AM
Scoop.it!

Do Zombies Dream of Undead Sheep?: A Neuroscientific View of the Zombie Brain

Do Zombies Dream of Undead Sheep?: A Neuroscientific View of the Zombie Brain

Product by Verstynen, Timothy/ Voytek, Bradley ~ Bradley Voytek (author) More about this product
List Price: $19.95
Price: $17.40
You Save: $2.55 (13%)
Do Zombies Dream of Undead Sheep?: A Neuroscientific View of the Zombie Brain [Timothy Verstynen, Bradley Voytek] on Amazon.com. *FREE* shipping on qualifying offers. Even if you've never seen a zombie movie or television show, you could identify an undead ghoul if you saw one. With their endless wandering
No comment yet.
Scooped by Ed Rybicki
February 22, 2016 6:04 AM
Scoop.it!

No-frills coats set a trend for designer viruses

No-frills coats set a trend for designer viruses | Virology News | Scoop.it
An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic biology
Ed Rybicki's insight:

Interesting: I missed this two years ago!  Great news.

No comment yet.
Scooped by Ed Rybicki
February 22, 2016 5:58 AM
Scoop.it!

Scientists Discover Novel Herpes Virus in Bats

Scientists Discover Novel Herpes Virus in Bats | Virology News | Scoop.it
A team of scientists, led by Dr. Reed Shabman of the J. Craig Venter Institute and Prof. Christopher Basler of the Icahn School of Medicine at Mount Sinai, New York, has isolated a novel gammaherpesvirus -- bat gammaherpesvirus 8 -- from the cells of the cave bat Myotis velifer incautus.
No comment yet.
Scooped by Ed Rybicki
February 22, 2016 5:56 AM
Scoop.it!

Equine Herpes Virus Updates for US states

Equine Herpes Virus Updates for US states | Virology News | Scoop.it
As winter marches on, so do reports of the highly contagious Equine Herpes Virus (EHV). The virus has been reported this month from coast to coast, and in boarding barns, training centers, racetracks...
No comment yet.